

# Francesca Moraca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7299805/publications.pdf>

Version: 2024-02-01

16  
papers

326  
citations

1040056

9  
h-index

888059

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

722  
citing authors

#	ARTICLE	IF	CITATIONS
1	The $\alpha$ 2 of gp120 is a regulatory switch for HIV-1 Env conformational transitions. <i>Nature Communications</i> , 2017, 8, 1049.	12.8	88
2	Inhibition of <i>Leishmania infantum</i> Trypanothione Reductase by Azole-Based Compounds: a Comparative Analysis with Its Physiological Substrate by X-ray Crystallography. <i>ChemMedChem</i> , 2013, 8, 1175-1183.	3.2	63
3	Discovery of the first potent and selective <i>Mycobacterium tuberculosis</i> Zmp1 inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2508-2511.	2.2	22
4	Application of Free Energy Perturbation (FEP+) to Understanding Ligand Selectivity: A Case Study to Assess Selectivity Between Pairs of Phosphodiesterases (PDEs). <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 2729-2740.	5.4	20
5	A fast virtual screening approach to identify structurally diverse inhibitors of trypanothione reductase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 5255-5258.	2.2	19
6	In vitro screening of 2-(1H-imidazol-1-yl)-1-phenylethanol derivatives as antiprotozoal agents and docking studies on <i>Trypanosoma cruzi</i> CYP51. <i>European Journal of Medicinal Chemistry</i> , 2016, 113, 28-33.	5.5	18
7	Binding Mode and Selectivity of Steroids towards Glucose-6-phosphate Dehydrogenase from the Pathogen <i>Trypanosoma cruzi</i> . <i>Molecules</i> , 2016, 21, 368.	3.8	16
8	Synthesis, biological evaluation and structure-activity correlation study of a series of imidazol-based compounds as <i>Candida albicans</i> inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2014, 83, 665-673.	5.5	15
9	New Promising Compounds with in Vitro Nanomolar Activity against <i>Trypanosoma cruzi</i> . <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 538-541.	2.8	14
10	In Vitro and In Vivo Inhibition of the <i>Mycobacterium tuberculosis</i> Phosphopantetheinyl Transferase PptT by Amidinoureas. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 1996-2022.	6.4	10
11	Computational Evaluation of HIV-1 gp120 Conformations of Soluble Trimeric gp140 Structures as Targets for de Novo Docking of First- and Second-Generation Small-Molecule CD4 Mimics. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 2069-2079.	5.4	9
12	Macrocyclic Peptides that Selectively Inhibit the <i>Mycobacterium tuberculosis</i> Proteasome. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 6262-6272.	6.4	9
13	Identification of gp120 Residue His105 as a Novel Target for HIV-1 Neutralization by Small-Molecule CD4-Mimics. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 1824-1831.	2.8	8
14	Recognition of HIV-inactivating peptide triazoles by the recombinant soluble Env trimer, BG505 SOSIP.664. <i>Proteins: Structure, Function and Bioinformatics</i> , 2017, 85, 843-851.	2.6	7
15	Specific Noncovalent Interactions Determine Optimal Structure of a Buried Ligand Moiety: QM/MM and Pure QM Modeling of Complexes of the Small-Molecule CD4 Mimetics and HIV-1 gp120. <i>ChemMedChem</i> , 2018, 13, 627-633.	3.2	4
16	Exploring the Activity Profile of TbrPDEB1 and hPDE4 Inhibitors Using Free Energy Perturbation. <i>ACS Medicinal Chemistry Letters</i> , 2022, 13, 904-910.	2.8	1